Primary Hyperoxaluria Type 1 (PH1)

Pediatric Academic Societies (PAS) 2026

Congress Details

April 24-27, 2026

Boston, MA, USA

The material below is provided to support scientific exchange and pertains to select congress resources. Any content about investigational therapeutics or investigational uses of locally approved products does not establish the safety or efficacy of these therapeutics or uses, and there is no guarantee of local regulatory approval.

All congress materials are copyrighted by Alnylam. Permission is required to copy or distribute.

For questions beyond a product’s authorized indications or for information not available here, please contact Alnylam Medical Information.

Agenda

25 April, 2026

Descriptive-Analysis-of-Real-World-Enrollment-Data-of-Pediatric-and-Adult-Patients-From-a-Global-Primary

Presentation Type

Poster

Time

3:30 PM - 5:45 PM EST

Location

Convention Center: Poster, Posters Hall

Title

Descriptive Analysis of Real-World Enrollment Data of Pediatric and Adult Patients From a Global Primary Hyperoxaluria Type 1 Registry (BONAPH1DE)

Presenter

Michelle Baum

Boston Children's Hospital, MA, USA

26 April, 2026

Presentation Type

Oral presentation

Time

2:45 PM - 3:00 PM EST

Location

Convention Center: 104AB West

Title

Long-Term Efficacy, Safety, and Growth Outcomes in the Phase 3 ILLUMINATE-B Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children

Presenter

David J. Sas

Mayo Clinic, MN, USA

26 April, 2026

Presentation Type

Oral presentation

Time

2:45 PM - 3:00 PM EST

Location

Convention Center: 104AB West

Title

Long-Term Efficacy, Safety, and Growth Outcomes in the Phase 3 ILLUMINATE-B Trial of Lumasiran for Primary Hyperoxaluria Type 1 in Infants and Young Children

Presenter

David J. Sas

Mayo Clinic, MN, USA

Pediatric Academic Societies (PAS) 2026

Congress Details

Agenda

Related Materials

Related Materials

Warning !

Confirmation !

Update Password